Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Mylan (MYL) to Report Q4 Earnings: What's in the Offing?

Investors will look forward to regular top and bottom-line numbers and updates on merger with Upjohn, when Mylan (MYL) reports Q4 results.

John Blank headshot

What Poses the Greatest Risk to Markets?

The Nov. election, coronavirus, or earnings results?

Deciphera's NDA for GIST Drug Gets Priority Review From FDA

The FDA accepts Deciphera's (DCPH) NDA for ripretinib and grants a priority review to the same for the treatment of advanced gastrointestinal stromal tumors.

Merck's Keytruda Meets PFS Endpoint in Breast Cancer Study

Merck's (MRK) immuno-oncology drug, Keytruda, significantly improves progression free survival as first-line treatment for metastatic triple-negative breast cancer patients in a pivotal study.

Pfizer's Xtandi Improves OS Rate in Prostate Cancer Study

Pfizer's (PFE) Xtandi demonstrates a significant improvement in overall survival in the late-stage PROSPER study that evaluated the drug in men with non-metastatic castration-resistant prostate cancer.

The Zacks Analyst Blog Highlights: Microsoft, JP Morgan Chase and Pfizer

The Zacks Analyst Blog Highlights: Microsoft, JP Morgan Chase and Pfizer

John Blank headshot

Coronavirus Update: Global Week Ahead

In the Global Week Ahead, the global economy and China will be reeling from the spread of a novel pneumonia or flu-like coronavirus.

Blueprint Medicines' NDA for Avapritinib Gets Extended Review

FDA extends review period for Blueprint Medicines' (BPMC) NDA seeking accelerated approval for avapritinib in fourth-line gastrointestinal stromal tumors by three months.

Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates

Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.

Glaxo (GSK) Lags Q4 Earnings & Revenue Estimates, Stock Down

Glaxo (GSK) misses on earnings and sales in the fourth quarter. The company expects earnings to decline in 2020.

Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat

Novo Nordisk (NVO) posts in-line earnings, while revenues beat estimates in the fourth quarter of 2019.

Merck's Recarbrio Gets FDA Priority Review for New Indication

The FDA accepts Merck's (MRK) sNDA for antibacterial injection Recarbrio and grants priority review.

Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q4 Earnings?

Investors will focus on the performance of Opdivo, Revlimid and Eliquis along with the regular top and bottom-line numbers when Bristol-Myers (BMY) reports fourth-quarter results.

The Zacks Analyst Blog Highlights: Amazon.com, Procter & Gamble, Pfizer, Southwest Airlines and Humana

The Zacks Analyst Blog Highlights: Amazon.com, Procter & Gamble, Pfizer, Southwest Airlines and Humana

Benjamin Rains headshot

3 Dividend-Paying Stocks for Investors to Buy to Fight Off Market Uncertainty

Check out these three dividend-paying stocks that investors might want to buy to help combat coronavirus-based market pullback fears...

Bristol-Myers' Opdivo-Yervoy NSCLC Application in EU Withdrawn

Bristol-Myers (BMY) has withdrawn its application in the EU for the Opdivo and Yervoy combo for the treatment of advanced NSCLC based on data from the CheckMate-227 study.

Is a Disappointment in Store for Glaxo's (GSK) Q4 Earnings?

Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales in the fourth quarter.

Sheraz Mian headshot

Q4 Earnings Scorecard and Analyst Reports for Amazon, Pfizer & Others

Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), The Procter & Gamble Company (PG) and Pfizer Inc. (PFE).

Lilly's Olumiant Succeeds in Another Late-Stage Eczema Study

Lilly's (LLY) JAK inhibitor Olumiant meets primary endpoint of phase III BREEZE-AD5 study, evaluating the drug as a monotherapy in atopic dermatitis patients.

Kinjel Shah headshot

Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative

Lilly (LLY), Pfizer (PFE) and Novartis (NVS) announce Q4 results.

Bayer Seeks FDA Approval for New Formulation of Nifurtimox

Bayer (BAYRY) files application to the FDA for the new formulation of nifurtimox to improve the body-weight adjusted dosing in pediatric Chagas patients.

Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More

Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.

Indrajit Bandyopadhyay headshot

Merck's Dificid Gets FDA Approval in Pediatric Indication

The FDA grants approval to Merck's (MRK) two regulatory applications seeking expanded approval for its antibacterial medicine, Dificid.

Benjamin Rains headshot

Apple, Starbucks & eBay Earnings Previews & A Strong Buy Retail Stock - Free Lunch

What investors can expect from Apple, Starbucks, and eBay earnings Tuesday. The episode then ends with why Guess?, Inc. (GES) is a Zacks Rank #1 (Strong Buy) stock right now...

Allergan to Divest Brazikumab, Zenpep to Close AbbVie Merger

Allergan (AGN) to divest autoimmune candidate, brazikumab and drug Zenpep in connection with its pending merger with AbbVie.